Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma

1 Citations

Journal

Citations (1)*help

See more

Details 詳細情報について

  • CRID
    1570291225649408384
  • NII Article ID
    10021256904
  • Data Source
    • CiNii Articles

Report a problem

Back to top